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Abstract
Background: Cell line immortalisation is a growing component of African genomics research and biobanking.
However, little is known about the factors influencing consent to cell line creation and immortalisation in African
research settings. We contribute to addressing this gap by exploring three questions in a sample of Xhosa participants
recruited for a South African psychiatric genomics study: First, what proportion of participants consented to cell line
storage? Second, what were predictors of this consent? Third, what questions were raised by participants during this
consent process?
Methods: 760 Xhose people with schizophrenia and 760 controls were matched to sex, age, level of education and
recruitment region. We used descriptive statistics to determine the proportion of participants who consented to cell
line creation and immortalization. Logistic regression methods were used to examine the predictors of consent.
Reflections from study recruiters were elicited and discussed to identify key questions raised by participants about
consent.
Results: Approximately 40% of participants consented to cell line storage. The recruiter who sought consent was a
strong predictor of participant’s consent. Participants recruited from the South African Eastern Cape (as opposed to the
Western Cape), and older participants (aged between 40 and 59 years), were more likely to consent; both these groups
were more likely to hold traditional Xhosa values. Neither illness (schizophrenia vs control) nor education (primary vs
secondary school) were significant predictors of consent. Key questions raised by participants included two broad
themes: clarification of what cell immortalisation means, and issues around individual and community benefit.
Conclusions: These findings provide guidance on the proportion of participants likely to consent to cell line
immortalisation in genomics research in Africa, and reinforce the important and influential role that study recruiters
play during seeking of this consent. Our results reinforce the cultural and contextual factors underpinning consent
choices, particularly around sharing and reciprocity. Finally, these results provide support for the growing literature
challenging the stigmatizing perception that people with severe mental illness are overly vulnerable as a target group
for heath research and specifically genomics studies.
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Background
Cell line creation and immortalisation is a growing compo-
nent of African genomics research and biobanking. The
process involves altering the genetic make-up of a human
body cell to allow it to continue reproducing indefinitely,
outside of the human body; providing an inexhaustible
resource for DNA and other cell products [1]. These prod-
ucts can then be used for a wide range of functional genet-
ics research [2]. Cell line creation and immortalisation in
African genomics studies would promote African represen-
tation in future functional genomics work, increase the
pertinence of discoveries and therapeutic applications to
African populations, while reducing the burden and cost to
African researchers and participants relating to additional
sample donations [1].
While some theoretical work has been done to explore
the broader ethical considerations relating to such practice
[1, 3], there is little empirical work describing the predictors
of consent to cell line creation and immortalisation in
African research settings. Many research participants from
low and middle income countries (LMICs) contend with
the challenges of poverty, limited access to healthcare, low
research and health literacy levels and unfamiliarity with
the research process, all of which may influence the consent
process for African genomic research and biobanking [4–6].
One reported challenge for seeking informed consent for
health research in LMIC settings is that procedures tend to
be complex and understanding of research study elements
varies considerably across participants [7, 8] – a challenge
that has also been identified in relation to informed consent
for African genomics research [5, 6, 9]. An influential power
dynamic between clinicians and the participants being re-
cruited for research has also been reported [7, 10]. However
we are unsure as to the influence of these factors on choices
about consent to the creation of cell lines for long-term
sample storage and re-use in the African setting. This article
aims to contribute to addressing this gap by examining
consent for cell immortalisation during enrollment into a
South African psychiatric genomics study. This paper is a
secondary analysis, using data collected from the Genomics
of Schizophrenia in South African Xhosa People (SAX)
project. Specifically, we consider the following questions:
First, what proportion of participants consented to cell line
storage? Second, what were predictors of this consent?
Third what questions were raised by participants about this
consent during recruitment?
Methods
The Genomics of Schizophrenia in South African Xhosa
people (SAX) project
As is the case for genomic research in general [11] current
psychiatric genomics research is under-representative of
African populations [12]. The SAX study aims to identify
mutations underlying predisposition to schizophrenia in
the Xhosa people. This study is designed to initiate this
kind of genomics research in Africa, and moreover, will be
informative for genomics research on schizophrenia
worldwide [13].
Recruitment and data collection
The SAX study recruits Xhosa people with schizophrenia
and Xhosa controls matched to sex, age, education level
and region recruited. Cases are recruited from provincial
psychiatric hospitals and clinics in the Eastern and Western
Cape provinces of South Africa, and include both in and
out-patients. Participants must have fulfilled the diagnostic
criteria for schizophrenia or schizoaffective disorder over at
least a two-year period. Controls are recruited from
university-affiliated general medical hospitals and commu-
nity health centers that draw from similar catchment areas
to the psychiatric hospitals.
All participants complete the University of California,
San Diego Brief Assessment of Capacity to Consent
Questionnaire (UBACC), a 10-item tool for evaluating
quality of understanding of different SAX study elements,
and identifying areas where participants require further
explanation [14, 15]. Next cases and controls complete the
Structured Diagnostic Interview for DSM-IV Axis I Disor-
ders (SCID-I) [16], along with other psychiatric measures.
All recruitment and clinical interview materials are ad-
ministered in Xhosa, having been translated in accordance
with the World Health Organization (WHO) translation
guidelines [17]. Participants then provide blood samples
for DNA analysis and HIV screening.
The SAX study uses a staged consent model where all
consenting participants agree to participate in the primary
genomic study. This involves a blood sample for DNA
analysis in the form of next generation sequencing. Partic-
ipants also consent at this stage to HIV testing in order to
account for any HIV related neurological complications.
Next, participants receive information about sample
(DNA) storage which they can choose to consent to. As a
third step, participants are given information about cell
immortalisation. This is an optional component requiring
an additional blood sample, and a refusal of cell line
creation does not affect eligibility to participate in the
primary genomic study. All three stages of consent are
discussed in person with the study recruiter at the time of
recruitment. Recruiters review the consent information
sheets with participants in Xhosa.
The information sheet outlining consent to cell line
creation provides the following explanation about cell
immortalisation:
“What does cell immortalisation entail? With
your permission, we would like to store your blood
cells in a way that they last forever (this is called
“immortalisation of cell lines”). This would make
Campbell et al. BMC Medical Ethics  (2018) 19:72 Page 2 of 7
it possible for researchers to study the DNA in
your blood cells in the future. DNA forms a set of
instructions, and in the future scientists could look
at these instructions in more detail. Right now, we
do not know what these ways of working may be.
It is possible that future work would lead to new
information and treatments of illnesses.
Potential risks and benefits: The reason somebody
might want to donate their cells is that it may allow
many scientists and researchers to learn about
illnesses far into the future. However immortalised
cells can last forever. These cells are also a more
detailed and accurate copy of your DNA. If you
wish to withdraw your data or your sample in the
future this is possible. However, please note that by
the time we withdraw your data or your sample, it
may already have been shared with other scientists.
Compensation: You will not receive any further
compensation for donating your cells.
What will happen with the information you
provide: Your immortalised cells and some of your
information will be shared with other scientists.
Your identifying information will not be shared.”
Data analysis
Participants recruited for the SAX study from March 2015
to November 2016 were included for analysis. Descriptive
statistics established the proportion of participants who
consented to cell line immortalisation. Logistic regression
methods were used to examine the predictors of consent
to cell line creation and immortalization. Consent to cell
line creation and immortalisation was used as the out-
come variable. We hypothesized that the recruiter would
play a significant role in consent [7]. SAX study recruiters
were all first language Xhosa speaking, professional
psychiatric nurses with clinical experience in a range of
psychiatric disorders. These recruiters ranged in age from
28 to 45 years, including one younger female psychiatric
nurse, and four male nurses of varying ages. All recruiters
lived in the Western Cape but most had lived in the East-
ern Cape for a period or had family living in the province.
However, none of the nurses had any previous experience
engaging with the psychiatric in- and out-patients at the
sites targeted for the SAX study. Anonymous letter codes
were assigned to each study recruiter (A-E). The recruiter
reporting the lowest consent rates was used as the refer-
ence nurse for the regression analysis.
The following additional categorical variables were
included in our analysis to explore possible associations:
absence/presence of a schizophrenia diagnosis (cases -
diagnosis of schizophrenia/ schizoaffective disorder or
controls - those presenting for treatment of other health
concerns), sex (male or female), age group (20–39 years or
40–59 years), education level (primary school – achieved
Grade 7 or less; secondary school – achieved Grade 8 or
more), region recruited from (Western Cape or Eastern
Cape) and HIV status (non-reactive or reactive). Data ana-
lysis was generated and managed using IBM SPSS Statis-
tics. Study recruiter reflections on key questions about cell
line creation posed by participants during recruitment
were recorded during a team discussion and salient
themes highlighted.
Results
Proportion and predictors of consent to cell line storage
The SAX study recruited a total of 1520 participants from
March 2015 to November 2016 or 760 matched pairs of
cases and controls, which were included for our analysis
here. Of these, 360 (23,6%) participants consented to
DNA storage for the SAX study only, 512 (33,6%) con-
sented to broad sample storage and 648 (42.6%) agreed to
the collection of an additional blood sample for cell line
creation. This subsample of participants who consented to
cell line creation included 308 (40.5%) cases with schizo-
phrenia and 340 (44.7%) unaffected controls. The study
recruiter was the strongest predictor of consent to cell line
creation and immortalisation. Other predictors of consent
included older age (40–59 years) and recruitment from
the Eastern Cape. A diagnosis of schizophrenia, sex,
education level and HIV status did not predict consent.
Results are summarized in Table 1 (Additional file 1).
Questions raised during the consent process
During the course of the SAX genomics project, we held
regular quality control and supervision meetings with the
study recruiters. At these meetings, we discussed challenges
encountered in enrollment, overall experiences, personal
opinions and also solicited feedback on the consent process.
We asked recruiters to recall questions raised by partici-
pants during the consenting process to cell line storage and
immortalization. These questions were noted and thematic-
ally analysed. Key questions retrospectively recalled by our
study recruiters, focused on two broad themes. The first
theme pertained to clarification of information already
outlined in the information sheet. Such questions included
further explanations about the cell line immortalisation
process and how it differed from DNA storage; clarification
about whether it was compulsory to donate blood samples
for cell line storage, where the blood would be stored and
for how long. Explanations of aspects of cell line immorta-
zation are complex and these recruiter experiences
highlight the importance of an iterative approach during
consent where the same recruiter identifies unclear aspects
of the study the participant may be struggling with, revisits
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and clarifies these details using alternative examples and
explanations when necessary.
A second theme pertained to benefit i.e.: who would
be benefitting from the storage of these samples and in
what ways? Examples included: What will the blood be
used for? Will I benefit from the future research that
may be done using these cells? Why will the samples be
stored in the US, and why for an indefinite period of
time? Can these samples be used by or sold to other
people, and if so how can you be sure these cells will be
used for the purposes initially intended? Do you trust
the people you are giving these cells to?
Discussion
Approximately 40% of participants in our study consented
to cell line creation and immortalisation, providing future
researchers with an indication of expected consent rates.
The study recruiter was the strongest predictor of consent
to cell line immortalisation. This may be due to personal
perspectives recuriters hold about the cell immortalisation
process, influencing how risks and benefits are empha-
sized and reiterated to participants during recruitment.
During discussions about challenges encountered in en-
rollment, over time, we noted a marked difference between
two recruiters in their views on cell immortalization. One
reported concern about the long term protection and use
of participant samples, while the other was more supportive
of the potential scientific advances that could be made as a
result of cell line immortalization and how these may even-
tually benefit the Xhosa community. When we analysed
consent rates, we noted that the more critical nurse con-
sented fewer participants to cell immortalization (Recruiter
E, n = 86, 20%) than the more supportive one (Recruiter A,
n = 230, 75%). Interestingly, Recruiters B and C, who
tended to take a more balanced perspective on both the
risks and benefits of cell immortalization maintained a con-
sent rate of 52% (n = 229) and 36% (n = 74) respectively.
While we did not monitor the consent process to explore
exactly how much time each recruiter spent on explaining
the various aspects of the procedure, it is likely that the
more critical recruiter spent more time describing risks and
challenges, whilst the more supportive recruiter spent more
time describing potential (scientific) benefits. This finding
illustrates the subtle influence recruiters hold over partici-
pants, and the need to be aware of and manage this poten-
tial bias during recruitment. In retrospect a more
thoroughly written explanation of potential risks and
benefits in the information sheet may have assisted here. In
addition, regular follow-ups on individual recruiter consent
rates during quality control meetings would have assisted
Table 1 Sample information, prevalence ratios and odds ratios of consent to cell line creation
Sample information Categories N (%) Consent to cell lines
N (%)
Odds Ratio CI: 95%
Total sample 1520 (100%) 648 (42.6%)
Absence/presence of schizophrenia diagnosis Controls 760 (50%) 340 (44.7%) 1.210 0.959–1.527
Cases 760 (50%) 308 (40.5%)
Sex: Female 184 (12.1%) 84 (45.7%) 1.166 0.822–1.655
Male 1336 (87.9%) 564 (42.2%)
Age: 40–59 532 (35%) 252 (47.4%) 1.308* 1.020-1.676
20–39 988 (65%) 396 (40.1%)
Education level: Secondary (≥Grade 8) 1130 (74.3%) 485 (42.9%) 1.041 0.791–1.370
Primary (≤Grade 7) 390 (25.7%) 163 (41.8%)
Recruitment region: Eastern Cape 878 (57.8%) 408 (46.5%) 1.597** 1.257-2.027
Western Cape 642 (42.2%) 240 (37.4%)
HIV status Reactive 185 (12.2%) 102 (55.1%) 1.306 0.912–1.871
Non-reactive 1335 (87.8%) 546 (40.9%)
SAX Recruiters
A 308 (20.3%) 230 (74.7%) 12.587** 8.815–17.972
B 437 (28.8%) 229 (52.4%) 4.802** 3.530–6.532
C 207 (13.6%) 74 (35.7%) 2.567** 1.754–3.757
D 130 8.6%) 29 (22.3%) 1.199 0.739–1.944
E (reference nurse) 438 (28.8%) 86 (19.6%)
*p < 0.05
**p < 0.01
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in addressing reasons for significant differences across
recruiters earlier on.
Older age was a second predictor of consent to cell line
creation and immortalisation in our sample. Overall 47,4%
of participants aged 40–59 years consented to cell line
immortalization in comparison with 40,1% of participants
aged 20–39 years. One explanation for this may involve
the power dynamic reported between the recruiter and
the participant, pertaining specifically to the recruiter’s
perceived competency [7, 10]. Some recruiters may be
perceived as having more knowledge and holding more
social status than the participant in particular Xhosa
communities. Within these communities there is a strong
emphasis on respect for social role. In these settings the
recruiter may be perceived by the participant to be acting
in their best interest. As a result the participant consents
to what they perceive the recruiter to be suggesting. This
may be particularly true of older participants who may
subscribe more closely to these traditional roles, and in so
doing forgo some degree of voluntariness in their consent.
A deeper awareness of these cultural norms encourages
recruiters to gently address this power dynamic when they
recognize it playing out in specific contexts, empowering
participants’ to make more informed decisions about their
willingness to consent.
Recruitment region was a third important predictor of
consent in our sample. Overall 46,5% of participants
recruited from the Eastern Cape consented to cell line
immortalization in comparison with 37,4% of partici-
pants recruited from the Western Cape. This result may
speak to the Ubuntu worldview which is particularly
prevalent in more traditional Xhosa communities, found
most commonly in the rural Eastern Cape. Ubuntu
emphasizes the importance of interconnectedness of
humans through positive regard for each other and
helpful humane interaction. It places emphasises on
reciprocity and accountability as key ethical values [18].
The Ubuntu worldview could imply broad support for
the concept of sharing of resources, including for instance
genomic data and samples in global health research
initiatives that may benefit future generations. Participants
recruited from the Western Cape where often recruited
from more urbanized areas that may be considered less
traditional.
While age and region of recruitment were significant
predictors of consent, Table 2 suggests that these variables
were fairly consistently distributed across recruiters, as was
HIV status. Importantly we did not find a significant
difference in likelihood to consent between our cases with
schizophrenia and unaffected controls, nor did we see a
difference between participants based on level of education.
Studies suggest that people with schizophrenia generally
show poorer understanding of research study elements
than healthy controls, despite demonstrating considerable
variability in terms of cognitive functioning [18–20],
making them potentially more vulnerable to the complex-
ities of consent to cell line storage. However we found that
after screening for the quality of understanding of SAX
study elements using the UBACC, a range of people re-
cruited as cases with schizophrenia and people recruited as
controls with other health-related problems, struggled to
demonstrate an adequate understanding of complex SAX
study elements after one review of the study consent mate-
rials, and benefitted significantly from further explanation
of certain elements in the form of iterative learning [14].
This rigorous iterative learning process is likely responsible
for why diagnosis and educational level were not predictors
of consent in our samples, and could be a valuable resource
for managing consent challenges in similar contexts and
population groups.
One important limitation of these results is that we did
not measure the time each study recruiter spent on
explaining the risks and benefits of cell line creation and
immortalization. While study recruiters are provided with
a consent script, they typically speak to this material when
recruiting participants allowing for a degree of improvisa-
tion, and seldom read the script verbatim. The influence
of time and attention to specific risks and benefits, par-
ticularly in more complex processes like cell lines creation,
would be an important consideration when investigating
rates of consent. A second limitation is that logistic
regression odds ratios do not approximate relative risks
for common outcomes. However the same patterns were
evident in looking at raw percentages.
Conclusions
These findings provide guidance on the proportion of
participants likely to consent to cell line immortalisation
Table 2 Recruiter statistics for: age, region recruited from and HIV status
Age Region HIV status
Recruiter 20–39 years 40–59 years Eastern Cape Western Cape Non-Reactive Reactive
A (n = 308) 193 (63%) 115 (37%) 185 (60%) 123 (40%) 253 (82%) 65 (18%)
B (n = 437) 283 (65%) 154 (35%) 243 (56%) 194 (44%) 386 (88%) 51 (12%)
C (n = 207) 151 (73%) 56 (27%) 96 (46%) 111 (54%) 181 (87%) 26 (13%)
D (n = 130) 103 (79%) 27 (21%) 89 (64%) 41 (36%) 116 (89%) 14 (11%)
E (n = 438) 258 (59%) 180 (41%) 265 (60,5%) 173 (39,5%) 399 (91%) 39 (9%)
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in genomics research, and reinforce the important and
influential role that individual recruiters play during the
seeking of this consent. Our results also suggest cultural
and contextual factors underpinning consent choices,
particularly around sharing and reciprocity. Furthermore
these results provide support for the growing literature
challenging the stigmatizing perception that people with
severe mental illness are overly vulnerable as a target group
for heath research and specifically genomics studies.
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Additional file 1: Database. The original database used for analysis in
this manuscript. (XLSX 66 kb)
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